Navigation Links
Smoked cannabis proven effective in treating neuropathic pain
Date:10/24/2007

Smoked cannabis eased pain induced in healthy volunteers, according to a study by researchers at the University of California, San Diego (UCSD) Center for Medical Cannabis Research (CMCR.) However, the researchers found that less may be more.

In the placebo controlled study of 15 subjects, a low dose of cannabis showed no effect, a medium dose provided moderate pain relief, and a high dose increased the pain response. The results suggest a "therapeutic window" for cannabis analgesia, according to lead researcher Mark Wallace, M.D., professor of anesthesiology at UCSD School of Medicine and Program Director for the UCSD Center for Pain Medicine.

The paper, to be published in the November issue of the journal Anesthesiology, is the second published study out of the CMCR. Headquartered at UCSD, the CMCR is collaboration between UCSD and UC San Francisco that was funded by a state-funded initiative in 1999 to rigorously study the safety and efficacy of medicinal cannabis in treating diseases.

The study used capsaicin, an alkaloid derived from hot chili peppers that is an irritant to the skin, to mimic the type of neuropathic pain experienced by patients with HIV/AIDS, diabetes or shingles brief, intense pain following by a longer-lasting secondary pain. The subjects were healthy volunteers who inhaled either medical cannabis or a placebo after pain was induced. The marijuana cigarettes were formulated under NIH supervision to contain either zero, two, four or eight percent delta-9-tetrahydrocannabinol (THC.)

Subjects reported a decrease in pain at the medium dose, and there was also a significant correlation between plasma levels of THC, the active ingredient in cannabis, and decreased pain, said Igor Grant, M.D., F.R.C.P.(C), professor and Executive Vice-Chair of the Department of Psychiatry, the director of the CMCR. Interestingly, the analgesic effect wasnt immediate; it took about 45 minutes for the cannabis to have an impact on the pain, he said.

The results, showing a medium-dose (4% THC by weight) of cannabis to be an effective analgesic, converged with results from the CMCRs first published study, a paper by UCSF researcher Donald Abrams, M.D. published in the journal Neurology in February 2007. In that randomized placebo-controlled trial, patients smoking the same dose of cannabis experienced a 34% reduction in HIV-associated sensory neuropathy paintwice the rate experienced by patients receiving a placebo.

This study helps to build a case that cannabis does have therapeutic value at a medium-dose level, said Grant. It also suggests that higher doses arent necessarily better in certain situations something also observed with other medications, such as antidepressants.

The researchers stated that more and larger studies need to be conducted to measure the efficacy of cannabis, noting that medical marijuana could play an important role in treating patients who dont respond well to the usual pain relievers or cant tolerate drugs such as ibuprofen or opioids used for severe pain.

The results of this study might help guide others doing clinical research into pain management, said Wallace.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Children Of Mothers Who Smoked Late In Pregnancies Tend To Be Smokers
2. Worlds 3 out of 10 Cigarettes Smoked in China
3. Zeta-Jones is obsessed With Smoked Salmon Sandwiches With Crushed Potato Chips
4. Cannabis for pain
5. Cannabis to be tested to help patients with respiratory diseases
6. Cannabis exerts protective effect against cancer
7. Relief For British MS Patients: Cannabis-Based Oral Spray
8. Alcohol And Drug Abuse (Cannabis) Leading Causes For Road Traffic Accidents
9. Government May Downgrade Cannabis
10. UK public misled over downgrading cannabis: Govt
11. Can Cannabis Cause Madness?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... In 2009, Carol Bryan endured ... in severe facial disfiguration. After four frightening years of isolation and emotional and ... Center, who removed the substances in a partial facial transplant through eight surgeries. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) ... who seek access to the Network’s programs and services in the greater Pittsburgh region. ... care appointments will be offered one for that same afternoon. , AHN ...
(Date:1/19/2017)... ... January 19, 2017 , ... St. Catherine’s Village announced that a limited number ... skilled nursing facility on the grounds of the St. Catherine’s Village campus in Madison, ... the best nursing home in Mississippi for the second year in a row by ...
(Date:1/19/2017)... ... ... Bill Howe Plumbing, Heating & Air in San Diego announces the official ... Your Heart Drawing Contest The drawing contest asks children to draw their idea ... Air receives over 600 entries. The culmination of the joint effort will be celebrated ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced ... and implement new sales and marketing strategies. Grover comes with a total of 15 ... and a half years as Executive Vice President of Direct Sales at Traeger® Wood ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... Massachusetts , January 19, 2017 ... ) announced that the U.S. Food and Drug Administration ... of a New Drug Application (NDA) for SHP465, a ... evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder ... on or around June 20, 2017, the designated Prescription ...
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
Breaking Medicine Technology: